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Abstract
Background: Patients with end-stage renal disease
(ESRD) and on hemodialysis (HD) are at increased risk
for developing rheumatoid arthritis (RA), as a result
of defective immunity. Our aim was to examine if
ESRD and the length of HD treatment impact the clin-
ical utility of antibodies to cyclic citrullinated peptides
(anti-CCP) and rheumatoid factor (RF) as diagnostic
tools for RA.
Methods: We included 94 subjects in our study: 37
healthy volunteers and 57 patients with ESRD who
had been undergoing HD for 1–12 years, and without
confirmed RA. In order to test our hypothesis, we
measured and correlated anti-CCP and RF as labora-
tory markers of RA.
Results: Our study showed that there is no significant
difference between values for anti-CCP (ps0.11) and
RF (ps0.98) in control subjects as well as in patients
undergoing HD, regardless of the length of time that
patients had been undergoing HD treatment.
Conclusions: Our study indicates that HD does not
impair the specificity of anti-CCP and RF for RA in
patients where the disease has not yet developed.
Future prospective studies may show whether there
is any use in determinating RF, and especially anti-
CCP, as early predictors of RA in patients with ESRD
who are at greater risk of developing this condition.
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Introduction
Hemodialysis (HD) as a treatment for end-stage renal
disease (ESRD) may ameloriate the primary disorder,
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but it also leads to the development of new ones,
especially in bones, joints and soft tissues (1).
Rheumatoid arthritis (RA), a systemic autoimmune
disorder of unknown ethiology causing chronic joint
inflammation, affects nearly 1% of the adult popula-
tion (2). Patients with ESRD on HD are at increased
risk for development of this condition. This risk is due
to decreased cellular and humoral immunity, and the
requirement for invasive procedures related to uri-
nary and vascular access which promotes bacteremia
(3). The 1987 American college of rheumatology
(ACR) criteria for RA includes: arthritis of three or
more joint areas and positive findings on hand radio-
graphs; arthritis of three or more joint areas including
metacarpophageal (MCP) and wrist joints; serum
rheumatoid factor (RF)-negative and negative findings
on hand radiographs; arthritis involving a single joint
area symmetrically and serum RF-positive; oligoar-
thritis of MCP or wrist joints and serum RF-positive.
Classification of RA is very important as new thera-
pies can halt the disease in its early stages. Anti-
bodies to cyclic citrullinated peptides (anti-CCP) are
widely used for diagnosis of RA, but are not part of
the 1987 ACR classification criteria (4). Anti-CCP anti-
bodies are highly specific for RA (95%–98%), and may
predict the development of RA before occurrence of
the first symptoms of the disease, as well as being
good indicators or prognosis (2, 5, 6). Anti-CCP anti-
bodies are more specific than RF for diagnosing RA,
and are better predictive factors for an erosive course
of disease (7).
RF are antibodies directed against antigenic deter-
minants of the Fc portion of IgG, and are increased in
70%–80% of patients with RA. They are also increased
in 5%–10% of healthy individuals (8).
Previous studies have shown in patients on HD high
levels of circulating immunocomplexes (9, 10) that
can result in immunological abnormalities and immu-
nosuppressive co-morbidities (3). Our goal was to
determine if ESRD and the length of HD impact the
utility of anti-CCP and RF as diagnostic markers for
RA. We also examined the relationship of these para-
meters. To test this hypothesis, we measured anti-
CCP and RF, comparing patients with ESRD being
treated with HD to a healthy control group.
Subjects, materials and methods
Subjects
The study was performed at the Clinical Department for Lab-
oratory Diagnostic at University Hospital Dubrava in Zagreb
from February to April 2008. The study was approved by
the Ethics Committee of University Hospital Dubrava. We
included 94 subjects in the study: 37 healthy volunteers in
our control group and 57 patients with ESRD who had been
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Table 1 Basic characteristics of control group and patients with ESRD on hemodialysis.
Parameter Control Patients with Patients on Patients on p-Value
group ESRD on hemodialysis hemodialysis
hemodialysis 1–5 years N1 5 years or more N2
n 37 57 32 25
Age, years (mean"SD) 50"7 54"13 54"13 55"12 0.14
Sex (male/female) 17/20 31/26 18/14 13/12 0.69
Bone erosions 0/37 19/52 8/29 11/23
ESRD, end-stage renal disease.
undergoing HD from 1 year to 12 years. One of the patients
in the studied group had been treated with continuous
ambulatory peritoneal dialysis (CAPD). The frequency of HD
was three times a week for 4 h (ns48), three times a week
for three and a half hours (ns6) and two times a week for
three and a half hours (ns2). The etiologies of ESRD were:
hypertension (ns19), glomerulonephritis (ns13), Balkan
endemic nephropathy (ns6), diabetes mellitus (ns5), poly-
cystic kidney disease (ns4), pyelonephritis (ns3), reflux
(ns2), kidney stones (ns2), glomerulonephritis combined
with hypertension (ns1), drug induced renal failure (ns1)
and hereditary kidney disease (ns1).
Demographics of the participants and the presence of
bone erosion as assessed by computed tomography, are
shown in Table 1. Five patients had no data available con-
cerning the presence of bone erosion.
Patients with ESRD and on HD were divided into two
groups, depending on how long they had been undergoing
HD (Table 1). The criteria for ESRD patients participating in
the study were as follows: patients treated with HD for at
least 12 months; and none of the subjects were diagnosed
with RA using common diagnostic procedures.
The criteria for the control group consisting of healthy
volunteers were as follows: none of the subjects had clinical
signs or symptoms of rheumatoid disease noted during
examination.
Materials
The values of anti-CCP and RF were measured in sera col-
lected from patients and controls.
Sera was obtained following centrifugation at 1006=g
for 15 min in a 35 R Rotina Hettich centrifuge (Tuttlingen,
Germany), and then stored at –208C until analysis.
Methods
Anti-CCP was measured using the microparticle enzyme
immunoassay (MEIA) method with the Abbott AxSym
(Chicago, IL, USA). The principle of the method is reaction
of anti-CCP from the sample with micro particles coated with
CCP. An antigen-antibody complex is formed on micro par-
ticles. Alkaline phosphatase conjugate is then added. After
the substrate is added (4-methylumbelliferyl phosphate),
alkaline phosphatase conjugate catalyzes the hydrolysis of
4-methylumbelliferyl phosphate, yielding the fluorescent
product 4-methylumbellyferon. The intensity of the fluores-
cence is proportional to the concentration of analyte in the
sample. The method was calibrated with six levels of anti-
CCP calibrators (Abbott Laboratories Inc, Chicago, IL, USA).
The manufacturer also provided two commercial control
samples containing either anti-CCP positive or anti-CCP
negative human plasma in phosphate buffer and showing
concentrations of 0.0–3.0 U/mL for the negative control,
and 14.0–34.0 U/mL for the positive control.
The reference interval for anti-CCP reported by the manu-
facturer is -3.0 U/mL.
RF was determined using an immunoturbidimetricmethod
on the Olympus AU2700 analyzer (Tokyo, Japan). The prin-
ciple of the method is reaction of RF with IgG, which coats
latex particles resulting in the formation of insoluble aggre-
gates. The absorbance of the created aggregates is propor-
tional to the concentration of RF in the sample.
The manufacturer provided two commercial control sam-
ples wITA Control seras (Olympus Life Science Research
Europa GmbH, Munich, Germany)x containing RF at concen-
trations of 21.1–31.7 IU/mL for ITA 1, and 48.1–72.2 IU/mL
for ITA 2.
The reference interval for RF reported by the manufacturer
is -14 IU/mL.
Statistical analysis
The Kolmogorov-Smirnov test was used to test for a normal
distribution of the data. The x2-test and one-way analysis of
variance (ANOVA) were used for data comparisons. A
p-0.05 was considered statistically significant. MedCalc
9.2.0.0 statistical software (MedCalc, Mariakerke, Belgium)
was used for statistical analysis.
Results
Values for anti-CCP and RF in the groups are shown
in Table 2.
All numerical parameters were normally distributed
(Table 1). Thus, the data were tested using parametric
analysis and shown as mean and SD. One-way ANO-
VA did not show statistically significant differences
between values for anti-CCP (ps0.11) and RF (ps0.98)
among groups (control group, N1 and N2), and the
values were within the manufacturer’s reference
interval. Correlation between anti-CCP and RF was not
statistically significant.
Results for analysis of quality control material for
the anti-CCP negative control, anti-CCP positive con-
trol, ITA 1 control serum and ITA 2 control serum were
within the manufacturer’s recommended ranges.
The frequency of increased values of anti-CCP
()3 U/mL) were as follows: 0/37 in the control group;
4/57 in all patients with ESRD and on HD (2/32 in the
subgroup on HD for 1–5 years, and 2/25 in the
subgroup on HD )5 years).
The frequency of increased values of RF ()14
IU/mL) were as follows: 1/37 in the control group; 2/
57 in all patients with ESRD and on HD (1/32 in the
subgroup on HD from 1–5 years, and 1/25 in the
subgroup on HD )5 years).
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Table 2 Anti-CCP and RF values of control group and ESRD patients on hemodialysis.
Parameter Control group Patients with Patients on Patients on p-Value
ESRD on hemodialysis hemodialysis
hemodialysis 1–5 years N1 5 years or more N2
Anti-CCP, U/mL 1.46"0.60 1.1"0.51 1.26"0.51 1.17"0.51 0.11
(mean"SD)
RF, IU/mL 6.38"3.03 6.43"5.03 6.32"6.05 6.57"3.42 0.98
(mean"SD)
ESRD, end-stage renal disease; anti-CCP, antibodies to cyclic citrullinated peptides; RF, rheumatoid factor.
Discussion
ESRD affects all body systems due to the significant
decrease in renal function. Changes in bones, joints
and soft tissues occur often (1, 3, 9, 10). This is par-
ticularly important for RA which is associated with
significant morbidity and mortality. It is important to
recognize this disease as soon as possible, in order
to implement therapy promptly and prevent further
deterioration. HD is the most common procedure
used for treating advanced and permanent renal fail-
ure. While the HD procedure has advanced signifi-
cantly and become simpler and more efficient, there
are still numerous adverse effects. Our patients were
divided into two groups based on years of treatment
with HD. We used a limit of 5 years of HD since it is
known that there may be signs of amyloidosis
(dialysis-related amyloidosis) following five or more
years of HD. Amyloidosis develops when proteins in
the blood form deposits in joints and tendons, caus-
ing pain and joint stiffness, as is the case with arthritis
(11). Patients on long-term peritoneal dialysis have
less disorders and prolonged residual renal function
(RRF) following 5 years of therapy (12). However, our
study included only one patient on long-term perito-
neal dialysis.
Previous studies reported a higher incidence of sep-
tic arthritis (3) and autoimmune complexes (9, 10) in
patients on HD. As anti-CCP is an early predictor of
RA (13, 14), and RF is the only diagnostic laboratory
test for diagnosis of RA (4), we wanted to determine
whether ESRD and HD treatment, as well as the
length of HD, affects the values of these parameters.
The high prevalence of autoimmune complexes in
hemodialyzed patients (9, 10) could point to the devel-
opment of autoimmune disorders. Thus, anti-CCP and
RF could be useful diagnostic tools for monitoring the
development of disease (15–17). Also, it is possible
that the HD procedure removes immune com-
plexes as well as the other auto-antibodies such as
anti-CCP and RF (18). This would explain the reason
why we did not find a statistically significant differ-
ence associated with length of HD.
Our results showed that anti-CCP and RF concen-
trations were not changed in patients with ESRD who
were on HD, as well as in the subgroups depending
on length of HD. These finding indicate that HD does
not impair the specificity of anti-CCP and RF meas-
urements. Also, it is possible that there is no value in
measuring the concentration of these two analytes for
early detection of RA in patients with ESRD. However,
this should be investigated by prospective monitoring
of patients. Previous studies have shown that anti-
CCP is an early predictor of RA, and that concentra-
tions correlate with disease severity (14). Our results
suggest that HD is not likely to be the trigger for
development of RA.
Since our results did not show increased values of
anti-CCP and RF, antibodies that are present in high
concentrations in patients with ESRD treated with HD
should be clearly identified. Future prospective stud-
ies may determine if there is any use in determinating
RF, and especially anti-CCP, as early predictors of RA
in ESRD patients who might be at greater risk of
developing this condition.
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